VTGN logo

VistaGen Therapeutics (VTGN)

Profile

Full Name

Vistagen Therapeutics, Inc.

Ticker Symbol

VTGN

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

June 21, 2011

Indexes

Not included

Website

http://www.vistagen.com

Employees

48

Key Details

Price

$2.11(+1.93%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$1.06M(+568.72% YoY)

Annual EPS

-$1.52(+82.14% YoY)

PE ratio

-

Next earnings date

Jun 11, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$2.11
VTGN price is $2.11

30-Day Relative Volume

0.57
VTGN 30-day relative volume is 0.57

Price Performance

Price Most recent change

+1.93%
VTGN price was up +1.93% on Apr 17, 2025

Price YTD change

-28.47%
VTGN price is down -28.47% since January 1st

Price 1-year change

-54.82%
VTGN price is down -54.82% year-on-year

Price 3-year change

-95.66%
VTGN price is down -95.66% over the past 3 years

Price Range

Price All-time high

$1890.00
VTGN price is currently -99.89% below its historical high of $1890.00

Price 3-year low

$1.62
VTGN price is currently +30.25% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$60.90M
VTGN market capitalization is $60.90 million

Market cap 3-year change

-81.8%
VTGN market capitalization is down -81.8% over the past 3 years

Market cap All-time high

$660.66M
VTGN market capitalization is currently -90.78% below its historical high of $660.66 million

Market cap sector rank

41.07%
VTGN market capitalization is higher than 41.07% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+6.8%
VTGN shares outstanding is up +6.8% year-on-year

Shares Outstanding 3-Year Change

+319.22%
VTGN shares outstanding is up +319.22% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.55
VTGN beta is 0.55

200-day SMA

$2.97
VTGN price is currently -28.86% below its 200-day simple moving average

50-day SMA

$2.59
VTGN price is currently -18.61% below its 50-day simple moving average

RSI

37.30
VTGN 14-day relative strength index is 37.30

Volume

0.57
VTGN 30-day relative volume is 0.57

ATR

$0.17
VTGN average true range is $0.17

10-day Historical Volatility

74.04%
VTGN 10-day historical volatility is 74.04%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$1.06M
VTGN annual revenue is $1.06 million

Revenue Analysts estimate

$657.50K
VTGN annual revenue is currently +61.83% higher than the consensus analysts' forecast

Revenue 1-year change

+568.72%
VTGN annual revenue is up +568.72% year-on-year

Revenue Sector rank

12.89%
VTGN annual revenue is higher than 12.89% of companies in Healthcare sector

EPS

EPS

-$1.52
VTGN annual earnings per share is -$1.52

EPS Analysts estimate

-$1.74
VTGN annual earnings per share is currently -12.39% lower than the consensus analysts' forecast

EPS 1-year change

+82.14%
VTGN annual earnings per share is up +82.14% year-on-year

EPS Sector rank

45.32%
VTGN annual earnings per share is higher than 45.32% of companies in Healthcare sector

Profit

Gross profit

-
VTGN annual gross profit value is unknown

Gross margin

-
VTGN annual gross profit margin value is unknown

Operating profit

-$33.02M
VTGN annual operating income is -$33.02 million

Operating margin

-3103.48%
VTGN annual operating profit margin is -3103.48%

Net income

-$29.36M
VTGN annual net profit is -$29.36 million

Net margin

-2759.59%
VTGN annual net profit margin is -2759.59%

Expenses

Total expenses

$34.09M
VTGN annual total expenses is $34.09 million

Operating expenses

$34.09M
VTGN annual total operating expenses is $34.09 million

Cost of goods sold

-
VTGN annual cost of goods sold value is unknown

Selling, general & administrative expenses

$14.06M
VTGN annual SGA is $14.06 million

Depreciation and amortization

$568.00K
VTGN annual depreciation & amortization is $568.00 thousand

Interest expense

-
VTGN annual interest expense value is unknown

Income tax

$4000.00
VTGN annual income tax is $4000.00

EBIT & EBITDA

EBIT

-$33.02M
VTGN annual earnings before interest & taxes is -$33.02 million

EBITDA

-$32.45M
VTGN annual EBITDA is -$32.45 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$123.65M
VTGN annual total assets is $123.65 million

Non current assets

$2.98M
VTGN annual long term assets is $2.98 million

Current assets

$120.67M
VTGN annual total current assets is $120.67 million

Cash and cash equivalents

$119.17M
VTGN annual cash & cash equivalents is $119.17 million

Accounts receivable

-
VTGN annual accounts receivable value is unknown

Inventory

-
VTGN annual inventory value is unknown

Liabilities

Total liabilities

$9.37M
VTGN annual total liabilities is $9.37 million

Long term liabilities

$4.24M
VTGN annual total long term liabilities is $4.24 million

Current liabilities

$5.12M
VTGN annual total current liabilities is $5.12 million

Accounts payable

$1.55M
VTGN annual accounts payable is $1.55 million

Debt

Total debt

$2.12M
VTGN annual total debt is $2.12 million

Total debt 1-year change

-21.8%
VTGN annual total debt is down -21.8% year-on-year

Long term debt

$1.57M
VTGN annual long term debt is $1.57 million

Short term debt

$550.00K
VTGN annual short term debt is $550.00 thousand

Equity & Capital

Shareholders equity

$114.29M
VTGN annual stockholders equity is $114.29 million

Book value

$114.29M
VTGN annual book value is $114.29 million

Retained earnings

-$356.21M
VTGN annual retained earnings is -$356.21 million

Working capital

$115.55M
VTGN annual working capital is $115.55 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$25.81M
VTGN annual cash flow from operations is -$25.81 million

Cash from operations 1-year change

+48.08%
VTGN annual cash flow from operations is up +48.08% year-on-year

Cash from investing

-$61.00K
VTGN annual cash flow from investing activities is -$61.00 thousand

Cash from investing 1-year change

+91.76%
VTGN annual cash flow from investing activities is up +91.76% year-on-year

Cash from financing

$128.40M
VTGN annual cash flow from financing activities is $128.40 million

Cash from financing 1-year change

+12434.49%
VTGN annual cash flow from financing activities is up +12434.49% year-on-year

CAPEX

CAPEX

$61.00K
VTGN annual capital expenditures is $61.00 thousand

CAPEX 1-year change

-71.23%
VTGN annual capital expenditures is down -71.23% year-on-year

Free Cash Flow

Free cash flow

-$25.87M
VTGN annual free cash flow is -$25.87 million

Free cash flow 1-year change

+48.18%
VTGN annual free cash flow is up +48.18% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
VTGN annual gross profit margin value is unknown

Operating margin

-3103.48%
VTGN annual operating profit margin is -3103.48%

Net margin

-2759.59%
VTGN annual net profit margin is -2759.59%

ROA & ROE

ROA

-40.57%
VTGN annual return on assets is -40.57%

ROE

-46.47%
VTGN annual return on equity is -46.47%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
VTGN price to earnings ratio value is unknown

PE ratio Sector rank

-
VTGN price to earnings ratio is unknown

PB Ratio

PB ratio

0.75
VTGN price to book ratio is 0.75

PB ratio Sector rank

38.09%
VTGN price to book ratio is higher than 38.09% of companies in Healthcare sector

PS Ratio

PS ratio

87.25
VTGN price to sales ratio is 87.25

PS ratio Sector rank

94.74%
VTGN price to sales ratio is higher than 94.74% of companies in Healthcare sector

Enterprise value

Enterprise value

-$12.10M
VTGN enterprise value is -$12.10 million

Enterprise value Sector rank

4.05%
VTGN enterprise value is higher than 4.05% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

0.23
VTGN EV/EBITDA is 0.23

EV/EBITDA Sector rank

69.54%
VTGN EV/EBITDA is higher than 69.54% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

23.55
VTGN annual current ratio is 23.55

Quick ratio

-
VTGN annual quick ratio value is unknown

Leverage

Debt to equity

0.00
VTGN annual debt to equity ratio is 0.00

Interest coverage ratio

-
VTGN annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
VTGN piotroski f-score value is unknown

Altman Z-Score

0.12
VTGN altman z-score is 0.12

Analyst ratings

Recent major analysts updates

Dec 7, 23 Jefferies
Buy
Nov 14, 23 Stifel
Buy
Sep 5, 23 Maxim Group
Buy
Aug 7, 23 Maxim Group
Buy
Jul 26, 22 Maxim Group
Hold
Jul 22, 22 William Blair
Market Perform
May 20, 21 Baird
Outperform
Feb 18, 21 Jefferies
Buy
Jan 4, 21 William Blair
Outperform
Oct 8, 20 Aegis Capital
Buy

Institutional Ownership

Similar stocks

ADVM logo
Adverum Biotechnologies (ADVM)
ACHL logo
Achilles Therapeutics (ACHL)
FORA logo
Forian (FORA)
IVVD logo
Invivyd (IVVD)
ANRO logo
Alto Neuroscience (ANRO)
ADAP logo
Adaptimmune Therapeutics (ADAP)
ZIVO logo
ZIVO Bioscience (ZIVO)
CCLD logo
CareCloud (CCLD)
GUTS logo
Fractyl Health (GUTS)
  • What is the ticker symbol for VistaGen Therapeutics?
  • Does VistaGen Therapeutics pay dividends?
  • What sector is VistaGen Therapeutics in?
  • What industry is VistaGen Therapeutics in?
  • What country is VistaGen Therapeutics based in?
  • When did VistaGen Therapeutics go public?
  • Is VistaGen Therapeutics in the S&P 500?
  • Is VistaGen Therapeutics in the NASDAQ 100?
  • Is VistaGen Therapeutics in the Dow Jones?
  • When was VistaGen Therapeutics's last earnings report?
  • When does VistaGen Therapeutics report earnings?
  • Should I buy VistaGen Therapeutics stock now?

What is the ticker symbol for VistaGen Therapeutics?

The ticker symbol for VistaGen Therapeutics is NASDAQ:VTGN

Does VistaGen Therapeutics pay dividends?

No, VistaGen Therapeutics does not pay dividends

What sector is VistaGen Therapeutics in?

VistaGen Therapeutics is in the Healthcare sector

What industry is VistaGen Therapeutics in?

VistaGen Therapeutics is in the Biotechnology industry

What country is VistaGen Therapeutics based in?

VistaGen Therapeutics is headquartered in United States

When did VistaGen Therapeutics go public?

VistaGen Therapeutics's initial public offering (IPO) was on June 21, 2011

Is VistaGen Therapeutics in the S&P 500?

No, VistaGen Therapeutics is not included in the S&P 500 index

Is VistaGen Therapeutics in the NASDAQ 100?

No, VistaGen Therapeutics is not included in the NASDAQ 100 index

Is VistaGen Therapeutics in the Dow Jones?

No, VistaGen Therapeutics is not included in the Dow Jones index

When was VistaGen Therapeutics's last earnings report?

VistaGen Therapeutics's most recent earnings report was on Feb 13, 2025

When does VistaGen Therapeutics report earnings?

The next expected earnings date for VistaGen Therapeutics is Jun 11, 2025

Should I buy VistaGen Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page